Bremelanotide (PT-141)
Melanocortin receptor agonist.
Editorial review: August 13, 2026Evidence snapshot
An FDA-approved product has a narrow sexual-health indication for certain premenopausal women. That does not validate unapproved products or other uses.
Reported experiences
Sexual desire and arousal
Reported topics are not established benefits.Risks and unknowns
Nausea, flushing, headache, blood-pressure changes, skin darkening
Context matters. Approval of one medicine, formulation, or use does not establish approval of products sold online or other uses. This page is educational and does not provide dosing or treatment advice.
Member discussion
Compare experiences with care.
Before posting: Describe firsthand observations and uncertainty. Do not prescribe, arrange transactions, or post private health information.
Join the discussion
Verified members can contribute to compound conversations.
No approved member reports yet. Thoughtful first contributions are welcome.